Guoyu Chen

Guoyu Chen

Auto-generated profile, based on publicly available information

Guoyu Chen

State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, Shanghai Cancer Institute, Shanghai, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Hepatology
Verified
Journal Article
Open access
YCYibin Che
Yibin Che
GCGuoyu Chen
Guoyu Chen
QGQianqian Guo
Qianqian Guo
YDYourong Duan
Yourong Duan
HFHaizhong Feng
Haizhong Feng
QXQiang Xia
Qiang Xia
Export Background and Aims: Gut microbiota are recognized to be important for anticancer therapy, yet the underlying mechanism is not clear. Here, through the analysis of clinical samples, we identify the mechanism by which the gut microbial metabolite butyrate inhibits hepatocellular carcinoma (HCC) and then explore new strategies for HCC treatment. Approach and Results: In our study, we demonstrate that gut microbial metabolite butyrate improves anticancer therapy efficacy by regulating intracellular calcium homeostasis. Using liquid chromatography-mass spectrometry analysis, we found that butyrate metabolism is activated in HCC patients compared with healthy individuals. Butyrate levels are lower in the plasma of HCC patients by gas chromatography mass spectrometry (GC-MS) analysis. Butyrate supplementation or depletion of short-chain Acyl-CoA dehydrogenase (ACADS), a key enzyme for butyrate metabolism, significantly inhibits HCC proliferation and metastasis. Profiling analysis of genes upregulated by butyrate supplementation or ACADS knockdown reveals that calcium signaling pathway is activated, leading to dysregulation of intracellular calcium homeostasis and production of reactive oxygen species (ROS). Butyrate supplementation improves the therapy efficacy of a tyrosine kinase inhibitor sorafenib. Based on these findings, we developed butyrate and sorafenib co-encapsulated mPEG-PLGA-PLL (PEAL) nanoparticles (NPs) coated with anti-GPC3 antibody ([email protected]) to prolong the retention time of drugs and enhance drug targeting, leading to high anticancer efficacy. [email protected] NPs significantly reduce HCC progression. In addition, [email protected] NPs display excellent HCC targeting with excellent safety. Conclusions: In conclusion, our findings provide new insight into the mechanism by which the gut microbial metabolites inhibit HCC progression, suggesting a translatable therapeutics approach to enhance the clinical targeted therapeutic efficacy.

3 January 2020 in Nature
Verified
Journal Article
Open access
PDF file
GPGuangdun Peng
Guangdun Peng
SSShengbao Suo
Shengbao Suo
GCGuizhong Cui
Guizhong Cui
FYFang Yu
Fang Yu
Ran WangRan Wang
Ran Wang
NJNaihe Jing
Naihe Jing
An Amendment to this paper has been published and can be accessed via a link at the top of the paper.